Skip to content

John D Roache

3 papers in the library · 2 citations · publishing 2019-2026

Papers

Sort Most recent Most cited

Combining DNA methylation features and clinical characteristics predicts ketamine treatment response for PTSD.

iScience January 16, 2026 Amir Valizadeh, John D Roache, Xinyu Zhang et al. 2 citations

Post-traumatic stress disorder (PTSD) exhibits extensive clinical and biological variability, making treatment challenging. The Consortium to Alleviate PTSD (CAP)-ketamine trial, the largest randomized study of ketamine for PTSD, found no overall benefit of ketamine over placebo, underscoring the necessity to identify responsive subgroups. Using pre-treatment blood DNA methylation profiles and...

Dose-related effects of ketamine for antidepressant-resistant symptoms of posttraumatic stress disorder in veterans and active duty military: a double-blind, randomized, placebo-controlled multi-center clinical trial.

Neuropsychopharmacology July 2022 Chadi G. Abdallah, John D Roache, Ralitza Gueorguieva et al.

This study tested the efficacy of repeated intravenous ketamine doses to reduce symptoms of posttraumatic stress disorder (PTSD). Veterans and service members with PTSD (n = 158) who failed previous antidepressant treatment were randomized to 8 infusions administered twice weekly of intravenous placebo (n = 54), low dose (0.2 mg/kg; n = 53) or standard dose (0.5 mg/kg; n = 51) ketamine....

A pilot randomized controlled trial of cognitive behavioral treatment for trauma-related nightmares in active duty military personnel.

Journal of Clinical Sleep Medicine November 26, 2019 Kristi E. Pruiksma, Daniel J. Taylor, Jim Mintz et al.

Study objectives: The aim of this study was to obtain preliminary data on the efficacy, credibility, and acceptability of Exposure, relaxation, and rescripting therapy for military service members and veterans (ERRT-M) in active duty military personnel with trauma-related nightmares. Methods: Forty participants were randomized to either 5 sessions of ERRT-M or 5 weeks of minimal contact control...

DOI: 10.5664/jcsm.8116 (opens in new tab) Full text (opens in new tab) Humans Treatment outcome Pilot projects Dreams +7